-
How This Clearing Firm Is Weathering The Coronavirus: 'More Agile And Nimble'
Wednesday, March 25, 2020 - 3:44pm | 580Read More...Global markets are volatile as the COVID-19 coronavirus continues to send fear and uncertainty through all assets in the investment spectrum. Velox Clearing, a tech-focused clearing firm, hired Michael Higgins as CEO last month. Higgins spoke with Benzinga about his role in positioning...
-
AcelRX Shares Should More Than Double On Painkiller Assets, Landenburg Says In Bullish Initiation
Thursday, August 16, 2018 - 11:19am | 436Read More...AcelRx Pharmaceuticals Inc (NASDAQ: ACRX), with two product candidates in its pipeline, is a specialty pharma company focusing on pain management therapies. The Analyst Landenburg Thalmann analyst Michael Higgins initiated coverage of AcelRx with a Buy rating and $7 price target. The...
-
Marinus Pharmaceuticals Has 3 Major Catalysts In 2018, Ladenburg Thalmann Says In Bullish Initiation
Wednesday, June 6, 2018 - 3:43pm | 375Read More...Marinus Pharmaceuticals Inc (NASDAQ: MRNS) is a developer of ganaxolone, a therapy intended to treat patients with a rare genetic disorder, and initial data is "looking good," according to Ladenburg Thalmann. The Analyst Analyst Michael Higgins initiated coverage of Marinus...
-
Analyst: Sage Therapeutics Holds A Breakthrough In Depression Treatment
Wednesday, June 6, 2018 - 3:04pm | 428Read More...Sage Therapeutics Inc (NASDAQ: SAGE) is a buy ahead of the commercial launch of its safer alternatives to existing antidepressants, according to Ladenburg Thalmann. The Analyst Ladenburg Thalmann's Michael Higgins initiated coverage of Sage Therapeutics' stock with a Buy rating and $...
-
Time To Buy Synergy Pharma, Roth Capital Says
Thursday, October 29, 2015 - 11:11am | 272Read More...The share price of Synergy Pharmaceuticals Inc (NASDAQ: SGYP) has appreciated by 88.35 percent over the last six months, from a low of $3.44 on May 5. Roth Capital’s Michael Higgins has reinitiated coverage of the company with a Buy rating and price target of $9.50. Higgins...
